KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Esperion Therapeutics (ESPR) Leases (2019 - 2026)

Esperion Therapeutics filings provide 7 years of Leases readings, the most recent being $2.9 million for Q4 2025.

  • On a quarterly basis, Leases fell 47.0% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 million, a 47.0% decrease, with the full-year FY2025 number at $2.9 million, down 47.0% from a year prior.
  • Leases hit $2.9 million in Q4 2025 for Esperion Therapeutics, down from $3.3 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $7.1 million in Q1 2024 to a low of $730000.0 in Q3 2022.
  • Median Leases over the past 5 years was $3.5 million (2021), compared with a mean of $3.6 million.
  • Biggest five-year swings in Leases: tumbled 80.35% in 2022 and later skyrocketed 563.26% in 2024.
  • Esperion Therapeutics' Leases stood at $1.9 million in 2021, then crashed by 45.42% to $1.0 million in 2022, then soared by 351.25% to $4.7 million in 2023, then rose by 17.93% to $5.5 million in 2024, then plummeted by 47.0% to $2.9 million in 2025.
  • The last three reported values for Leases were $2.9 million (Q4 2025), $3.3 million (Q3 2025), and $4.2 million (Q2 2025) per Business Quant data.